Vertex Pharmaceuticals (VRTX) Stock News

Vertex Pharmaceuticals (Nasdaq: VRTX) has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. for its groundbreaking product JOURNAVX™ (suzetrigine). The recognized treatment is a first-in-class, non-opioid oral medication that works as a selective NaV1.8 pain signal inhibitor for treating moderate-to-severe acute pain in adults.

The recognition comes from Premier's annual Innovation Celebration program, which received approximately 120 nominations this year. Vertex will be formally honored at Premier's Breakthroughs Conference and Exhibition on July 15, 2025.

Vertex Pharmaceuticals (NASDAQ:VRTX) has scheduled its second quarter 2025 financial results announcement for Monday, August 4, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET.

Investors can access the call via U.S. dial-in at (833) 630-2124 or internationally at +1 (412) 317-0651, referencing "Vertex Pharmaceuticals Second Quarter 2025 Earnings Call". A live webcast will be available through the Investors section of Vertex's website. Participants are advised to register 15 minutes before the scheduled webcast.

Vertex Pharmaceuticals (NASDAQ: VRTX) has received European Commission approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily CFTR modulator for treating cystic fibrosis in patients 6 years and older with at least one non-class I mutation in the CFTR gene.

The approval follows successful head-to-head clinical trials where ALYFTREK® demonstrated non-inferiority to KAFTRIO® on ppFEV1 and showed superiority in reducing sweat chloride, indicating greater improvement in CFTR function. This new treatment will be accessible to approximately 31,000 eligible CF patients in the EU.

Initial access to the treatment will be available in Ireland, Denmark, and Germany through existing reimbursement agreements and healthcare provisions, with Vertex working to secure access across other EU member states.

Vertex Pharmaceuticals and Ono Pharmaceutical have announced an exclusive collaboration and license agreement for povetacicept development and commercialization in Japan and South Korea. Povetacicept, a recombinant fusion protein therapeutic, acts as a dual antagonist of BAFF and APRIL cytokines, showing best-in-class potential for treating IgA nephropathy (IgAN) and primary membranous nephropathy (pMN). Under the agreement, Vertex will receive an upfront payment, milestone payments, and tiered royalties. Ono will leverage its regional expertise to advance clinical trials, obtain marketing authorizations, and handle commercialization in these markets. The partnership aims to expand treatment options for patients with B cell-mediated diseases, with potential for additional indications beyond IgAN and pMN.

Vertex Pharmaceuticals (VRTX) presented positive Phase 1/2 data for zimislecel (VX-880), a stem cell-derived islet cell therapy for type 1 diabetes, at the American Diabetes Association conference. The study included 12 patients who received a full dose and were followed for at least one year. All patients achieved ADA-recommended targets of HbA1c 7% and 70% time-in-range, with 10 out of 12 becoming insulin-free. The therapy demonstrated consistent and durable benefits, with all patients showing glucose-responsive endogenous C-peptide production and freedom from severe hypoglycemic events after day 90. The treatment was generally well-tolerated, with most adverse events being mild or moderate. Two patient deaths occurred but were unrelated to zimislecel. The data was simultaneously published in the New England Journal of Medicine, and Vertex plans potential regulatory submissions next year.

Vertex Pharmaceuticals presented new data at the European Cystic Fibrosis Conference demonstrating the benefits of ALYFTREK and the importance of lower sweat chloride levels in cystic fibrosis treatment. The pooled analysis showed that reducing sweat chloride levels below 60 mmol/L led to improved outcomes, including better lung function, fewer pulmonary exacerbations, improved nutritional status, and enhanced quality of life. Notably, levels below 30 mmol/L showed even greater numerical benefits. Post hoc analysis from Phase 3 trials indicated that ALYFTREK treatment resulted in better health-related quality of life outcomes in adolescents and adults compared to TRIKAFTA, while also improving CF symptoms and general functioning in children aged 6-11 years.

Vertex Pharmaceuticals (NASDAQ: VRTX) has announced its management team's participation in three upcoming investor conferences in May and June 2025:

1. Evercore Biotechnology Summit (May 21) - Featuring Susie Lisa, SVP of Investor Relations, and Manisha Pai, Executive Director of IR

2. Bernstein 41st Annual Strategic Decisions Conference (May 30) - CEO Dr. Reshma Kewalramani will participate in a fireside chat at 8:00 a.m. ET

3. Goldman Sachs 46th Annual Global Healthcare Conference (June 10) - Dr. Kewalramani and Dr. David Altshuler, EVP of Global Research and CSO, will join a fireside chat at 2:40 p.m. ET

Live webcasts will be available on Vertex's website with replays archived in the Investors section.

Vertex Pharmaceuticals (VRTX) reported Q1 2025 financial results with total revenue of $2.77 billion, up 3% year-over-year. U.S. revenue increased 9% to $1.66 billion, while international revenue declined 5% to $1.11 billion due to IP violations in Russia. The company raised its 2025 revenue guidance to $11.85-$12 billion. GAAP net income was $646 million, down from $1.1 billion in Q1 2024, impacted by a $379 million impairment charge for VX-264. Key highlights include strong TRIKAFTA/KAFTRIO performance, successful launches of CASGEVY, ALYFTREK, and JOURNAVX, with over 20,000 JOURNAVX prescriptions filled since March. The company maintains robust cash position of $11.4 billion and continues advancing multiple clinical programs, including povetacicept and zimislecel Phase 3 trials.

Vertex Pharmaceuticals (Nasdaq: VRTX) announced that Paul Negulescu, Ph.D., Senior Vice President, has been awarded the prestigious 2025 Canada Gairdner International Award for his groundbreaking research in cystic fibrosis (CF). The award recognizes his pioneering work in understanding CF's cellular and molecular mechanisms, leading to transformative drug therapies.

Under Negulescu's leadership, Vertex developed the first-ever protein folding corrector medicines that treat CF's underlying cause. The company's most recent achievement is a triple combination therapy that can treat over 90% of CF patients with more than 300 different mutations through once-daily dosing.

Vertex currently has five approved CF medicines that restore function of the defective CFTR protein. The research team continues to develop new therapies, including an mRNA approach in clinical development, targeting the remaining 10% of patients who don't respond to existing treatments.